FMP
NeuBase Therapeutics, Inc.
NBSE
NASDAQ
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
0.434 USD
0.0137 (3.16%)
About
ceo
Mr. Todd P. Branning
sector
Healthcare
industry
Biotechnology
website
https://www.neubasetherapeutics.com
exchange
NASDAQ
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pi...
CIK
0001173281
ISIN
US64132K2015
CUSIP
64132K102
Address
350 Technology Drive
Phone
646 450 1790
Country
US
Employee
37
IPO Date
May 28, 2004
Summary
CIK
0001173281
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
64132K102
ISIN
US64132K2015
Country
US
Price
0.43
Beta
0.96
Volume Avg.
236.23k
Market Cap
1.63M
Shares
-
52-Week
0.39-4.8
DCF
10.63
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.02
P/B
-
Website
https://www.neubasetherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NBSE News
It looks like there's no news available.
